IBT Examines Strategies Aimed At Promoting Antibiotic Drug Development
International Business Times: Antibiotic Resistance: Why Aren’t Drug Companies Developing New Medicines To Stop Superbugs?
“…[A]s many as 10 million people a year could die from antibiotic-resistant bacteria worldwide by 2050 if new treatments are not discovered, according to a recent report from the Review on Antimicrobial Resistance. … Despite that urgency, most of the world’s largest pharmaceutical companies stopped making antibiotics long ago, citing high costs of development and low returns. … Therefore, only a fraction of the medicines that are needed are being produced…” (Nordrum, 3/3).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.